Loading...
•
Sep 30, 2022
Veracyte Q3 2022 Earnings Report
Veracyte's Q3 2022 financial results were announced, with total revenue growing to $75.6 million, a 25% increase compared to the third quarter of 2021.
Key Takeaways
Veracyte reported a 25% increase in total revenue for Q3 2022, reaching $75.6 million. The company saw growth in test volume and expanded reimbursement contracts. They are raising full-year 2022 total revenue expectations to $288 million to $293 million.
Total revenue increased by 25% to $75.6 million compared to Q3 2021.
Total test volume grew by 26% to 26,374 compared to Q3 2021.
Received positive coverage decisions for Decipher Prostate Genomic Classifier from three commercial payers, bringing the total number of covered lives for the test to 195 million.
Signed four new commercial payer contracts for the Afirma Genomic Sequencing Classifier, bolstering the test’s in-network coverage to over 230 million health plan members.
Revenue by Segment
Forward Guidance
The company is raising full-year 2022 total revenue expectations to $288 million to $293 million, representing year-over-year growth of 31% to 33%, assuming currency rates as of November 2, 2022.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...